Lenvatinib + Pembrolizumab
Phase 2Active 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Adenoid Cystic Carcinoma
Conditions
Adenoid Cystic Carcinoma, Salivary Gland Cancer
Trial Timeline
Jun 2, 2020 → Dec 1, 2026
NCT ID
NCT04209660About Lenvatinib + Pembrolizumab
Lenvatinib + Pembrolizumab is a phase 2 stage product being developed by Eisai for Adenoid Cystic Carcinoma. The current trial status is active. This product is registered under clinical trial identifier NCT04209660. Target conditions include Adenoid Cystic Carcinoma, Salivary Gland Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04645602 | Phase 1 | Recruiting |
| NCT04209660 | Phase 2 | Active |
| NCT03776136 | Phase 2 | Completed |
| NCT03609359 | Phase 2 | Completed |
| NCT03006887 | Phase 1 | Completed |
| NCT02501096 | Phase 1/2 | Completed |
Competing Products
11 competing products in Adenoid Cystic Carcinoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Enfortumab Vedotin | Astellas Pharma | Phase 2 | 52 |
| Lenvatinib | Eisai | Phase 2 | 52 |
| P-Sam | AstraZeneca | Phase 2 | 52 |
| Cetuximab | Merck | Phase 1/2 | 41 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| Dovitinib | Novartis | Phase 2 | 52 |
| Dovitinib (TKI258) | Novartis | Phase 2 | 52 |
| AG-013736 (AXITINIB) | Pfizer | Phase 2 | 51 |
| Regorafenib | Bayer | Phase 2 | 49 |
| Mometasone Furoate nasal spray + Placebo | Organon | Phase 3 | 72 |
| mometasone furoate nasal spray | Organon | Approved | 80 |